Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00006119
- Lead Sponsor
- UNICANCER
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.
- Detailed Description
OBJECTIVES:
* Determine complete, partial, or stable response to hydroxyurea in patients with recurrent and/or nonresectable meningioma.
* Determine response at 2 years to this regimen in these patients.
* Determine overall and disease free survival of these patients after this regimen.
* Determine quality of life of these patients.
* Determine the toxicities of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to grade of disease (I vs II or III).
Patients receive oral hydroxyurea daily for 2 years.
Quality of life is assessed before treatment, then every 3 months for 2 years.
PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Hopital Saint Andre
🇫🇷Bordeaux, France
Centre Hospitalier Universitaire Bretonneau de Tours
🇫🇷Tours, France
Centre Eugene Marquis
🇫🇷Rennes, France
Centre Leon Berard
🇫🇷Lyon, France
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
🇫🇷Montpellier, France